Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 05 2022
26 05 2022
Historique:
received:
17
01
2022
accepted:
05
05
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
As one of the most malignant cancers and despite various treatment breakthroughs, the prognosis of hepatocellular carcinoma (HCC) remains unsatisfactory. The immune status of the tumor microenvironment (TME) relates closely to HCC progression; however, the mechanism of immune cell infiltration in the TME remains unclear. In this study, we performed a new combination algorithm on lncRNA expression profile data from the TCGA-LIHC cohort to identify lncRNAs related to immune disorders. We identified 20 immune disorder-related lncRNAs and clustered HCC samples based on these lncRNAs. We identified four clusters with differences in immune cell infiltration and immune checkpoint gene expression. We further analyzed differences between groups 1 and 3 and found that the poor prognosis of group 3 may be due to specific and non-specific immunosuppression of the TME, upregulation of immune checkpoint pathways, and activation of tumor proliferation and migration pathways in group 3. We also developed a prognostic model and verified that it has good stability, effectiveness, and prognostic power. This study provides a basis for further exploration of the immune cell infiltration mechanism in HCC, differential HCC prognosis, and improvement of the efficacy of ICIs for the treatment of HCC.
Identifiants
pubmed: 35618810
doi: 10.1038/s41598-022-13013-7
pii: 10.1038/s41598-022-13013-7
pmc: PMC9135727
doi:
Substances chimiques
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8905Informations de copyright
© 2022. The Author(s).
Références
J Immunol. 2014 Oct 15;193(8):3835-41
pubmed: 25281753
Cancers (Basel). 2021 Apr 18;13(8):
pubmed: 33919570
J Exp Med. 2006 Apr 17;203(4):883-95
pubmed: 16606670
BMC Cancer. 2020 Dec 3;20(1):1185
pubmed: 33272262
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Nat Commun. 2021 Oct 12;12(1):5955
pubmed: 34642316
Front Immunol. 2019 Mar 08;10:420
pubmed: 30906297
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Semin Oncol. 2014 Apr;41(2):217-34
pubmed: 24787294
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Front Oncol. 2020 Sep 23;10:560229
pubmed: 33072587
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638469
Oncogene. 2020 Jun;39(23):4507-4518
pubmed: 32366907
Oncology. 2017;92 Suppl 1:50-62
pubmed: 28147363
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34645670
Nat Commun. 2017 May 25;8:15129
pubmed: 28541302
J Hepatol. 2022 Feb;76(2):353-363
pubmed: 34648895
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Ann Surg. 2006 Feb;243(2):229-35
pubmed: 16432356
Front Cell Dev Biol. 2021 Jul 07;9:698296
pubmed: 34307375
J Transl Med. 2020 Jun 22;18(1):245
pubmed: 32571340
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Front Cell Dev Biol. 2021 Sep 27;9:720791
pubmed: 34646823
Curr Oncol Rep. 2019 May 17;21(7):60
pubmed: 31101991
Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):34-42
pubmed: 23147664
Gastroenterology. 2008 May;134(6):1752-63
pubmed: 18471552
Elife. 2013 Jul 23;2:e00762
pubmed: 23898399
Front Oncol. 2021 Sep 27;11:725181
pubmed: 34646770
Cancers (Basel). 2021 Oct 04;13(19):
pubmed: 34638465
Nat Commun. 2013;4:2612
pubmed: 24113773
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Cancers (Basel). 2021 Sep 24;13(19):
pubmed: 34638266
Biol Open. 2019 Oct 17;8(10):
pubmed: 31575545
Hepatology. 2016 Dec;64(6):2047-2061
pubmed: 27177928